Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anaphylaxis: Revision of the Brighton collaboration case definition
Michael Gold, Ananda Amarasinghe, Matthew Greenhawt, et al.
Vaccine (2022) Vol. 41, Iss. 15, pp. 2605-2614
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Anaphylaxis: A 2023 practice parameter update
David B.K. Golden, Julie Wang, Susan Waserman, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 2, pp. 124-176
Open Access | Times Cited: 90
Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach
Matthew Greenhawt, Timothy E. Dribin, Elissa M. Abrams, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 2, pp. 309-325
Open Access | Times Cited: 13
An Update in COVID-19 Vaccine Reactions in 2023: Progress and Understanding
Kimberly G. Blumenthal, Matthew Greenhawt, Elizabeth J. Phillips, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 11, pp. 3305-3318
Open Access | Times Cited: 11
JYNNEOS vaccine safety surveillance during the 2022 mpox outbreak using the Vaccine Adverse Event Reporting System (VAERS) and v-safe, United States, 2022—2023
Jonathan Duffy, Tanya R. Myers, Paige Marquez, et al.
Sexually Transmitted Diseases (2024) Vol. 51, Iss. 8, pp. 509-515
Closed Access | Times Cited: 4
Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan
Suminobu Ito, Nao Tsuchida, Susumu Kusunoki, et al.
Vaccine (2025) Vol. 49, pp. 126754-126754
Open Access
Updates in food anaphylaxis management
Phil Lieberman, Elissa M. Abrams, Priya Katari, et al.
The Journal of Allergy and Clinical Immunology In Practice (2025)
Closed Access
Anaphylaxis versus inducible laryngeal obstruction: a diagnostic dilemma
Bethany Tidmarsh, Siobhan Ludlow, Stephen J. Fowler
BMJ Case Reports (2025) Vol. 18, Iss. 3, pp. e264236-e264236
Closed Access
Incidence and Factors Associated with Self-Reported Skin Symptoms of Allergic Reactions to COVID-19 Vaccines
Karnsinee Thanborisutkul, Prapasri Kulalert, Kanthida Methaset, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 289-289
Open Access
Allergische Reaktionen auf COVID-19-Impfstoffe – noch relevant?
Michael Lorenz
hautnah (2025)
Open Access
Revaccination outcomes among adolescents and adults with suspected hypersensitivity reactions following COVID-19 vaccination: A Canadian immunization research network study
Tiffany Fitzpatrick, Peter Yamoah, Gina Lacuesta, et al.
Vaccine (2024) Vol. 42, Iss. 24, pp. 126078-126078
Open Access | Times Cited: 3
mRNA COVID-19 vaccine safety among children and adolescents: a Canadian National Vaccine Safety Network cohort study
Phyumar Soe, Otto G. Vanderkooi, Manish Sadarangani, et al.
The Lancet Regional Health - Americas (2024) Vol. 40, pp. 100949-100949
Open Access | Times Cited: 3
Knowledge gaps in the diagnosis and management of anaphylaxis
Dana Wallace
Annals of Allergy Asthma & Immunology (2023) Vol. 131, Iss. 2, pp. 151-169
Closed Access | Times Cited: 7
Anaphylaxis: Definition and criteria
Marcus Shaker
Journal of Food Allergy (2024) Vol. 6, Iss. 1, pp. 26-31
Open Access | Times Cited: 2
Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy
Stefania Nicola, Marina Mazzola, Luca Lo Sardo, et al.
Vaccines (2024) Vol. 12, Iss. 2, pp. 202-202
Open Access | Times Cited: 2
A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination
Muhammad Bilal Khalid, Ellen Zektser, Eric Chun‐Pu Chu, et al.
Journal of Allergy and Clinical Immunology (2024) Vol. 153, Iss. 6, pp. 1634-1646
Open Access | Times Cited: 2
How to define severity
Ami Shah, Timothy E. Dribin, Julie Wang
Annals of Allergy Asthma & Immunology (2023) Vol. 131, Iss. 2, pp. 170-175
Closed Access | Times Cited: 5
COVID-19 in the Asia Pacific: impact on climate change, allergic diseases and One Health
Ruby Pawankar, Bernard Yu‐Hor Thong, Marysia T. Recto, et al.
Asia Pacific Allergy (2023)
Open Access | Times Cited: 5
Identifying and Managing Those at Risk for Vaccine-Related Allergy and Anaphylaxis
Cosby A. Stone, Lene H. Garvey, Shuaib Nasser, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 7, pp. 2008-2022
Open Access | Times Cited: 4
Analysis of allergy and hypersensitivity reactions to COVID-19 vaccines according to the EudraVigilance database
Jan Romantowski, Wojciech Nazar, Kinga Bojahr, et al.
(2024)
Open Access | Times Cited: 1
Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study
Nicoletta Luxi, Francesco Ciccimarra, Chiara Bellitto, et al.
Vaccines (2024) Vol. 12, Iss. 9, pp. 1059-1059
Open Access | Times Cited: 1
Safety signal detected: Anaphylaxis after attenuated dengue vaccine (TAK-003) – Brazil, march 1, 2023-march 11, 2024
Jadher Pércio, Carla Dinamerica Kobayashi, Roberta Mendes Abreu Silva, et al.
Vaccine (2024) Vol. 42, Iss. 26, pp. 126407-126407
Closed Access | Times Cited: 1
Post-licensure Safety Surveillance of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among US Adults in the Vaccine Adverse Event Reporting System (VAERS)
Mayra Martho Moura de Oliveira, Paige Marquez, Carol Ennulat, et al.
Drug Safety (2024)
Closed Access | Times Cited: 1
Adverse Effects Associated with the First Dose of the Pfizer–BioNTech COVID-19 Vaccine in Healthcare Workers from Mexico: A Case Serie from Passive Surveillance
Orlando Rubén Pérez‐Nieto, César Daniel Alonso-Bello, Ernesto Deloya-Tomás, et al.
COVID (2023) Vol. 3, Iss. 8, pp. 1209-1219
Open Access | Times Cited: 3
National assessment strategy for adults and children with a history of vaccine allergy shows low utility of COVID‐19 vaccine skin testing
Carmen Riggioni, Kee Fong Phang, Sen Hee Tay, et al.
Pediatric Allergy and Immunology (2023) Vol. 34, Iss. 2
Open Access | Times Cited: 2
Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study
Lucy Deng, Kathryn Tapper, Deepali Thosar, et al.
Vaccine (2023) Vol. 41, Iss. 41, pp. 5987-5993
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top